Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.070
EU - Europa 2.404
AS - Asia 1.017
AF - Africa 26
SA - Sud America 16
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
Totale 11.542
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.063
IT - Italia 666
FI - Finlandia 559
CN - Cina 534
SG - Singapore 337
DE - Germania 287
UA - Ucraina 205
IE - Irlanda 157
GB - Regno Unito 134
SE - Svezia 112
RU - Federazione Russa 89
RO - Romania 54
BE - Belgio 47
FR - Francia 45
IN - India 40
TR - Turchia 29
CI - Costa d'Avorio 25
KR - Corea 22
IR - Iran 15
CH - Svizzera 10
NL - Olanda 9
ES - Italia 8
HK - Hong Kong 8
UZ - Uzbekistan 7
PL - Polonia 6
BR - Brasile 5
CA - Canada 5
EU - Europa 5
CL - Cile 4
LB - Libano 4
CZ - Repubblica Ceca 3
IL - Israele 3
JP - Giappone 3
KZ - Kazakistan 3
TW - Taiwan 3
AR - Argentina 2
AU - Australia 2
CO - Colombia 2
GR - Grecia 2
ID - Indonesia 2
LU - Lussemburgo 2
MY - Malesia 2
NO - Norvegia 2
PE - Perù 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
BD - Bangladesh 1
BG - Bulgaria 1
DK - Danimarca 1
EC - Ecuador 1
EE - Estonia 1
JM - Giamaica 1
LT - Lituania 1
LV - Lettonia 1
MA - Marocco 1
MC - Monaco 1
MO - Macao, regione amministrativa speciale della Cina 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
VN - Vietnam 1
Totale 11.542
Salva come PNG Salva come JPEG
Città #
Fairfield 1.439
Ashburn 785
Woodbridge 765
Wilmington 575
Chandler 572
Seattle 570
Houston 529
Cambridge 526
Ann Arbor 494
Singapore 280
Palermo 169
Dublin 155
Medford 141
Des Moines 122
Altamura 118
Nanjing 110
Jacksonville 107
Princeton 90
Lawrence 80
Santa Clara 72
San Diego 71
Beijing 55
Boardman 53
New York 51
Dearborn 50
Brussels 46
Tulsa 41
Ludwigshafen am Rhein 39
Changsha 36
London 33
Nanchang 33
Shenyang 33
Phoenix 32
Hebei 29
Jiaxing 28
Bremen 27
Tianjin 26
Abidjan 25
Izmir 25
Helsinki 23
Jinan 22
Kitzingen 22
Kumar 21
Saint Petersburg 20
Seongnam 20
Milan 19
Zhengzhou 18
Ningbo 16
San Paolo di Civitate 15
Munich 13
Hangzhou 12
Venice 12
Washington 12
Chicago 11
Guangzhou 11
Los Angeles 11
Berlin 10
Tehran 9
Norwalk 8
Pune 8
Rome 8
Verona 8
Columbus 7
Frankfurt am Main 7
Hong Kong 7
Kilburn 7
Shanghai 6
Taiyuan 6
Auburn Hills 5
Chengdu 5
Frankfurt Am Main 5
Fuzhou 5
Hanover 5
Kunming 5
Orange 5
San Mateo 5
Cagliari 4
Hefei 4
Indiana 4
Islington 4
Moscow 4
Mountain View 4
Redmond 4
Redwood City 4
St Petersburg 4
Taizhou 4
Tappahannock 4
Zurich 4
Detroit 3
Haikou 3
Marano di Napoli 3
Montepulciano 3
Napoli 3
New Delhi 3
Nürnberg 3
San Francisco 3
Taipei 3
Vigliano Biellese 3
Walnut 3
Wandsworth 3
Totale 8.925
Salva come PNG Salva come JPEG
Nome #
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 216
Dietary restriction: could it be considered as speed bump on tumor progression road? 212
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations 203
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 200
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 192
Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 181
How Much of Familial Breast Cancer Risk is Currently Explained by the Known Genes? 181
Anti-endothelin drugs in solid tumors 180
A headlight on liquid biopsies: a challenging tool for breast cancer management 179
EGFR genomic alterations in cancer: prognostic and predictive values 175
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 173
HER2-positive male breast cancer: An update 172
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 170
MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets 169
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 166
BRCA1 and BRCA2 variants of uncertain clinical significance and their implications for genetic counseling 165
EGF Induces STAT3-Dependent VEGF Expression in HT-29 colon cancer cells 165
I tumori della mammella e/o dell’ovaio di tipo eredofamiliare: strategie di prevenzione nelle donne ad alto rischio 164
Nintedanib in NSCLC: Evidence to date and place in therapy 164
Targeted Therapies in Hepatocellular Carcinoma 163
HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions 162
Monoclonal antibodies in gastrointestinal cancers 162
BRCA1 and BRCA2 germline mutations in sicilian breast and/or ovarian cancer families and their association with familial profiles 160
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment 154
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 154
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 154
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? 153
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis 152
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 151
The role of targeted therapy for gastrointestinal tumors 151
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide 150
Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors 150
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense? 150
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 150
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 150
MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness? 149
Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines 149
Multisciplinary management of patients with liver metastasis from colorectal cancer 145
The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies 143
A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients 142
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting 142
BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 142
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 142
Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy 141
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 140
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 140
Sex steroids, carcinogenesis, and cancer progression 140
Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy? 138
Cancer and the microbiome: Potential applications as new tumor biomarker 135
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma 133
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 133
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer 132
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 132
Well-being among Italian medical oncologists: An exploratory study 131
Downregulated expression of Cdc25A gene in MCF-7 breast cancer cell 130
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 129
Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer 129
Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor 127
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? 125
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 118
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 118
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 117
Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules 116
How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer? 114
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 114
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 113
Studio pilota sul valore predittivo dei livelli plasmatici di 9 fattori angiogenetici nella selezione di pazienti candidati alla biopsia prostatica 110
Bortezomib: a new pro-apoptotic agent in cancer treatment. 109
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 108
Ramucirumab and its use in gastric cancer treatment 106
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 104
Comparison between gemcitabine-based combination (G) and single-agent chemotherapy (S) for elderly patients (EP) with advanced non-small cell lung cancer (NSCLC): A literature-based meta-analysis. 100
A literature-based meta-analysis of the comparison between Gemcitabine-based combination and monochemotherapy for the treatment of advanced non-small cell lung cancer in elderly patients 96
Low dose splenic irradiation in myelofibrosis: outcomes and toxicity of three radiation schedule 94
Plasma levels of angiogenetic markers in men candidate to prostate biopsy 92
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 90
Impact of the new 5-HT3 receptor antagonist palonosetron (P) in chemotherapy-induced nausea and vomiting (CINV) control in elderly advanced breast cancer (EABC) patients: Comparison with the classic antiemetic agent ondansetron (O). 88
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma 85
Apoptosis in Thyroid Autoimunity. 84
Serum levels of angiogenetic cancer biomarkers in men undergoing prostate biopsy. Preliminary data 81
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 79
VIPoma and PPoma 78
Efficacy of weekly low-dose chemotherapy in elderly women with advanced ovarian cancer: is there an antiangiogenic effect? 73
Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility? 73
An all-oral combination regimen of vinorelbine and capecitabine for elderly patients with metastatic breast cancer 68
A non common BRAF mutation c1799-1801 delTGA identified in sporadic colon rectal cancer of sicilian patients 68
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers 66
Capecitabine (XEL) + Oxaliplatin (OX) in elderly people (EP) with Colorectal Cancer (CRC): Comparison of safety (S) and feasibility (F) of two different schedules. Preliminary findings 64
Safety and efficacy of two different schedules of capecitabine combined with oxaliplatin in the treatment of colon cancer in the elderly 53
RECHALLENGE WITH ANTI-EGFR MONOCLONAL ANTIBODIES IN PRETREATED METASTATIC COLORECTAL CANCER PATIENTS: BEYOND THE LIMITS OF ACQUIRED RESISTANCE 47
Totale 12.008
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.658
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.658
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.754 0 0 0 0 0 392 323 266 291 187 210 85
2020/20211.493 117 82 88 130 85 32 124 118 162 224 159 172
2021/20221.317 58 284 72 64 63 50 72 86 117 153 102 196
2022/20231.649 176 354 31 197 183 230 109 110 154 6 67 32
2023/2024666 29 87 51 51 47 132 64 86 7 10 9 93
2024/2025617 25 151 184 136 60 61 0 0 0 0 0 0
Totale 12.008